GlaxoSmithKline PLC (LON:GSK) Rating Reaffirmed
Exane BNP Paribas now has a GBX 1400.00 TP on the 64.32B GBP market cap company or 5.78% upside potential. In an analyst note sent to clients and investors on Tuesday, 8 December, GlaxoSmithKline PLC (LON:GSK) shares have had their Neutral Rating maintained by research analysts at Exane BNP Paribas.
From a total of 24 analysts covering GlaxoSmithKline PLC (LON:GSK) stock, 6 rate it a ”Buy”, 4 a “Sell”, and 20 a ”Hold”. This means that 20% of the ratings are positive. The highest target price is GBX 1800 while the lowest target price is GBX 1250. The mean of all analyst targets is GBX 1470.25 with a 11.03% above today’s (GBX 1327) stock price. GlaxoSmithKline PLC was the topic of 95 analyst reports since July 28, 2015 according to the firm StockzIntelligence Inc. BNP Paribas maintained shares on December 7 with “Neutral” rating. Goldman Sachs maintained shares with “Buy” rating and GBX 1800 target share price in a report from a November 24. Liberum Capital maintained GSK stock in a recent report from December 3 with “Hold” rating. J.P. Morgan maintained the rating on November 20. J.P. Morgan has a “Neutral” rating and a GBX 1370 price target on shares. Finally, Bernstein maintained the stock with “Market Perform” rating in a report issued on a December 1.
Approximately 126,138 shares of stock traded hands. GlaxoSmithKline plc (LON:GSK) has declined 10.42% since May 11, 2015 and is downtrending. It has underperformed by 9.83% the S&P500.
GlaxoSmithKline plc. is a healthcare firm that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The company has a market cap of 64.32 billion GBP. The Firm operates in two divisions: Pharmaceuticals and Vaccines, and Consumer Healthcare. It has 6.53 P/E ratio. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases.
According to Zacks Investment Research, “GlaxoSmithKline is one of the world’s leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.” Get a free copy of the Zacks research report on GlaxoSmithKline plc (GSK).